



***BioAlliance Pharma publishes  
its 2010 financial calendar***

**Paris, December 22, 2009** – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has announced its financial calendar for 2010:

<b>February 9, 2010</b>	<b>Publication of the annual revenue statement for 2009</b>
<b>March 3, 2010</b>	<b>Publication of the consolidated accounts for 2009</b>
<b>March 4, 2010</b>	<b>SFAF analyst meeting at the Company's head office</b>
<b>April 1, 2010</b>	<b>Publication of the Company's financial annual report and French "Document de Référence" for 2009</b>
<b>April 22, 2010</b>	<b>Annual General Meeting at the Company's head office</b>
<b>April 22, 2010</b>	<b>Publication of the revenue statement for Q1 2010</b>
<b>July 22, 2010</b>	<b>Publication of the revenue statement for Q2 2010</b>
<b>August 25, 2010</b>	<b>Publication of the consolidated half-year accounts as of June 30 2010</b>
<b>August 26, 2010</b>	<b>SFAF analyst meeting at the Company's head office</b>
<b>October 21, 2010</b>	<b>Publication of the revenue statement for Q3 2010</b>

All financial press releases are published after stock market closing.

Along with other information on BioAlliance Pharma S.A., a regularly updated "Investors" section is available on the company's website ([www.bioalliancepharma.com](http://www.bioalliancepharma.com)).

### **About BioAlliance Pharma**

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com).

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).*

### **BioAlliance Pharma SA**

Dominique Costantini, President and CEO

Tel.: +33 1 45 58 76 01

[dominique.costantini@bioalliancepharma.com](mailto:dominique.costantini@bioalliancepharma.com)

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

### **ALIZE RP**

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

[caroline@alizerp.com](mailto:caroline@alizerp.com)